The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Enhanced Version of Accolade? Launched

11 Feb 2009 07:00

RNS Number : 1190N
Sopheon PLC
11 February 2009
 



Embargoed Release: 07:00hrs Wednesday 11th February 2009

Sopheon Plc

("Sopheon" or the "Company")

Sopheon Launches Enhanced Version of Accolade® Product Lifecycle Management Software 

Latest Version of Accolade® Enables Right Choices on Where to Cut and 

Where to Spend to Survive Recession and Protect Business Future 

MINNEAPOLIS and LONDON-Feb11, 2009-Sopheon, the international supplier of software and services for product lifecycle management ("PLM"), today announces it has launched an enhanced version of its Accolade® product portfolio and innovation process management solution. Features being introduced in the software provide advanced decision support to help senior executives more effectively prioritise product innovation investments and keep available resources focused on projects promising high business returns. The new capabilities are expected to bring immediate value to recession-plagued companies that need to reduce costs and are concerned about undercutting long-term growth strategies. 

The current business environment is perceived as the most uncertain that many organisations have ever faced. As the depth or duration of the recession remains unpredictable, business leaders are being forced to continually reconsider strategies and adjust plans and priorities based on constant infusion of new, mostly negative data. Evidence is growing that spending on product innovation not only helps to sustain business success during a downturn, it generates dramatic financial benefits when markets recover.  A study by the Strategic Planning Institute found that, during the past 30 years, companies that continued to invest in innovation during periods of recession generated 23.8% returns on capital employed when turnarounds occurred, compared with 0.6% for organisations that cut product development budgets*. Innovation has the capacity to transform crisis into opportunity.

New Accolade® Gives Product Innovators Five Critical Advantages In Addressing Recessionary Challenges  

In today's turbulent markets, the ability to make product innovation decisions and portfolio adjustments quickly is not only a competitive differentiator, it is a survival skillAccolade® software brings together the critical pieces needed in any economic climate to drive business results from product innovation: strategic planning, portfolio management, and end-to-end process automation and governanceThe solution's value is amplified during a recession because it provides planning and decision-making support that helps companies to not only maximise returns from available resources while times are toughbut to develop programmes and strategies that will allow them to accelerate out of the downturn and emerge with increased competitive strength. Through their use of Accolade®, organisations are able to:      

1) Improve strategic agility and “uncertainty planning”
Accolade® supports agility in strategic planning by rapidly moving decision-relevant information both vertically and horizontally inside the organisation. The easy flow of data allows senior executives to know and react quickly when project details change or external events suddenly demand adjustments or refinements to active strategies. 
 
2) Make faster, better-informed portfolio decisions
Strong portfolio management helps organisations optimise limited resources. Accolade® makes it possible to see in real time where innovation resources are invested. The solution’s dashboards consolidate, aggregate and present metrics so that information can be monitored at a glance. The new version of the software allows all innovation plans and projects to be stored in one place so that access is quick and easy. 
 
3) Identify, prioritise and act on the most promising innovation opportunities
Accolade® allows users to separate winning products from losers early in the development cycle and to keep investments concentrated on high-value opportunities. Software features such as scorecards, tailored selection criteria, resource reports and information-gathering and presentation templates grounded in best practices strengthen process governance and minimise innovation risk. 
 
4) Keep daily operational activities aligned with organisational strategies for growth
An estimated 65% of companies struggle to keep product portfolios and operational and project activity aligned with corporate strategic plans. Sopheon’s solution creates a seamless, automated process and decision framework that continually reconciles strategic product planning and operational execution.  
5) Cut costs by improving innovation process and team efficiencies

According to recent Gartner research, companies whose PLM priorities include deployment of technology applications such as Sopheon’s Accolade® can reduce product development costs by 30% or more. The savings happen because users are able to identify and abandon low-value or non-strategic projects early, before valuable resources are spent on development.

"Today's economic crisis is a time of great opportunity for companies that understand the business importance of continuedprudent investment in product innovation," said Andy Michuda, Sopheon's chief executive officer"Since the market downturna growing list of top organisations such as Bayer HealthCare, Burger King, Novartis, PepsiCand the U.S. Army have adopted our software. At the same time, current customers such as General Motors, Medtronic, Lockheed Martin, SABMiller and Verizon Wireless are extending the use of our solutions across their organisations. Anecdotal evidence indicates that increasingly, these investments are being made not in spite of the recession, but because of it."

The latest version of Sopheon's Accolade® software is available immediately for purchase and implementation. 

Accolade® is a registered trademark of Sopheon plc.

*"Profit Impact of Market Strategy" (PIMS) study 

-END-

For further information contact:

Barry Mence, Chairman

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Vikki Krause

Hansard Communications

+ 44 (0) 207 245 1100

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

Paul Davies, Corporate Finance

Seymour Pierce

+ 44 (0) 207 107 8000

About Sopheon

Sopheon (LSE:SPE) is an international provider of software and services that help organisations improve the business impact of product innovation. Sopheon's Accolade® solution automates the product innovation process and provides decision support for the management of product portfolios. Its Vision Strategist™ offering automates the strategic product roadmapping process, allowing users to visualise and forecast the future of products, markets and technologies. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Euronext in the Netherlands. For more information, please visit www.sopheon.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEANAEFADNEFE
Date   Source Headline
21st Feb 20247:00 amRNSCancellation - Sopheon Plc
20th Feb 20244:31 pmRNSScheme of Arrangement becomes Effective
20th Feb 20247:30 amRNSSuspension - Sopheon plc
16th Feb 20241:40 pmRNSIssue of Equity, PDMR Dealing and Rule 2.9
16th Feb 20241:35 pmRNSCourt Sanction of Scheme of Arrangement
16th Feb 20249:04 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
14th Feb 20248:32 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20245:30 pmRNSSopheon
9th Feb 20243:30 pmRNSForm 8.3 - SPHN LN
9th Feb 20249:35 amRNSForm 8.3 - Sopheon plc
9th Feb 20249:14 amRNSForm 8.5 (EPT/NON-RI)
8th Feb 20242:00 pmRNSResults of Court Meeting and General Meeting
17th Jan 20241:31 pmRNSHolding(s) in Company
17th Jan 20249:42 amRNSForm 8.3 - Sopheon plc
16th Jan 20245:45 pmRNSPublication of Scheme Document
15th Jan 202410:53 amRNSForm 8.3 - Sopheon plc
15th Jan 20248:13 amRNSForm 8.3 - SOPHEON PLC
12th Jan 20243:22 pmRNSForm 8.3 - Sopheon PLC
11th Jan 20248:50 amRNSSatisfaction of NSIA Condition
11th Jan 20248:49 amRNSForm 8.3 - SOPHEON PLC
10th Jan 20249:13 amRNSForm 8.3 - SOPHEON PLC
9th Jan 202412:35 pmRNSForm 8.3 - Sopheon plc
9th Jan 20248:48 amRNSForm 8.3 - SOPHEON PLC
8th Jan 202412:22 pmRNSIssue of Equity
8th Jan 20248:31 amRNSForm 8.3 - SOPHEON PLC
4th Jan 20249:45 amRNSForm 8.3 - SOPHEON PLC
2nd Jan 20245:18 pmRNSForm 8.3 - Sopheon Plc
2nd Jan 20249:07 amRNSForm 8.3 - SOPHEON PLC
22nd Dec 20231:00 pmRNSRecommended Cash Offer
15th Dec 20238:39 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 20238:32 amRNSForm 8.5 (EPT/NON-RI)
12th Dec 202310:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 20238:37 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 202310:41 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20238:36 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20239:16 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 20236:18 pmRNSRule 2.9 Announcement
4th Dec 202312:30 pmRNSIssue of Equity
28th Nov 20237:00 amRNSOffer update - extension to PUSU Deadline
17th Nov 202311:39 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:30 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20232:59 pmRNSForm 8.3 - SOPHEON PLC
10th Nov 202311:40 amRNSForm 8.5 (EPT/NON-RI)
10th Nov 202311:09 amRNSForm 8.3 - Rivomore Limited - Sopheon plc - Amend
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202312:57 pmRNSForm 8.3 - Sopheon plc
8th Nov 202310:25 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
8th Nov 20237:00 amRNSForm 8 (OPD) Sopheon plc
7th Nov 202311:24 amRNSForm 8.5 (EPT/NON-RI)
6th Nov 20231:03 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.